Revenues - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended
	Jul. 13, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
License And Collaboration Agreements [Line Items]
Total collaboration and license revenues		$ 25	$ 18
Deferred revenue recognized		25	$ 18
Gilead
License And Collaboration Agreements [Line Items]
Cost sharing receivable		4
Gilead | Prepaid Expenses and Other Current Assets
License And Collaboration Agreements [Line Items]
Capitalized Contract Cost, Net, Current		1
Gilead | Other Noncurrent Assets
License And Collaboration Agreements [Line Items]
Capitalized Contract Cost, Net, Noncurrent		$ 3
Customer Concentration Risk | Gilead | Revenue Benchmark
License And Collaboration Agreements [Line Items]
Percentage of revenues		100.00%	89.00%
Gilead Collaboration Agreement
License And Collaboration Agreements [Line Items]
Deferred revenue		$ 427		$ 452
Gilead Collaboration Agreement | Gilead
License And Collaboration Agreements [Line Items]
Deferred revenue		177
Total collaboration and license revenues		8	$ 5
Deferred revenue recognized	$ 121	219
Current and future programs exclusive access period	10 years
Contingent milestone payments receivable	$ 300
Option continuation payment receivable upon sixth anniversary of agreement	$ 100
Performance obligation period	4 years
R&D activities for Domvanalimab
License And Collaboration Agreements [Line Items]
Deferred revenue		29
Total collaboration and license revenues		1	1
Deferred revenue recognized		34
Quemliclustat, License and R&D services | Gilead
License And Collaboration Agreements [Line Items]
Deferred revenue		142
Total collaboration and license revenues		8	2
Deferred revenue recognized		176
R&D and Commercialization Activities for Zimberelimab
License And Collaboration Agreements [Line Items]
Deferred revenue recognized		11
Access rights and option continuation periods
License And Collaboration Agreements [Line Items]
Deferred revenue		79
Total collaboration and license revenues		$ 8	$ 8